← Product Code [MLM](/submissions/CH/subpart-b%E2%80%94clinical-chemistry-test-systems/MLM) · K060385 # EMIT 2000 TACROLIMUS ASSAY AND SAMPLE PRETREATMENT REAGENT (K060385) _Dade Behring, Inc. · MLM · Apr 6, 2006 · Clinical Chemistry · SESE_ **Canonical URL:** https://fda.innolitics.com/submissions/CH/subpart-b%E2%80%94clinical-chemistry-test-systems/MLM/K060385 ## Device Facts - **Applicant:** Dade Behring, Inc. - **Product Code:** [MLM](/submissions/CH/subpart-b%E2%80%94clinical-chemistry-test-systems/MLM.md) - **Decision Date:** Apr 6, 2006 - **Decision:** SESE - **Submission Type:** Traditional - **Regulation:** 21 CFR 862.1678 - **Device Class:** Class 2 - **Review Panel:** Clinical Chemistry ## Indications for Use The Emit® 2000 Tacrolimus Assay is for in vitro quantitative analysis of tacrolimus and metabolite in human whole blood as an aid in the management of tacrolimus therapy in liver and kidney transplant patients. The Emit® 2000 Tacrolimus Sample Pretreatment Reagent is an accessory reagent for use with the Emit® 2000 Tacrolimus Assay. ## Device Story Emit® 2000 Tacrolimus Assay is an immunoassay for quantitative measurement of tacrolimus and metabolite in human whole blood; used to manage therapy in liver and kidney transplant patients. Process requires manual pretreatment using Emit® 2000 Tacrolimus Sample Pretreatment Reagent; reagent lyses cells, extracts tacrolimus, and precipitates blood proteins. Following centrifugation, supernatant is assayed. Assay utilizes mouse monoclonal antibodies with high specificity for tacrolimus. Results assist clinicians in monitoring drug levels to optimize therapeutic management. ## Clinical Evidence Method comparison study conducted at two external sites (n=197 for LC/MS/MS comparison; n=192 for Abbott IMx comparison). Samples included liver and kidney transplant patients. Linear regression analysis performed. Correlation (r) with LC/MS/MS was 0.940 (all samples), 0.899 (kidney), 0.946 (liver). Correlation (r) with Abbott IMx was 0.881 (all samples), 0.863 (kidney), 0.812 (liver). ## Technological Characteristics Immunoassay system; utilizes mouse monoclonal antibodies. Requires manual sample pretreatment (cell lysis, protein precipitation, centrifugation). Assay range 2-30 ng/mL. In vitro diagnostic use. ## Regulatory Identification A tacrolimus test system is a device intended to quantitatively determine tacrolimus concentrations as an aid in the management of transplant patients receiving therapy with this drug. This generic type of device includes immunoassays and chromatographic assays for tacrolimus. ## Special Controls *Classification.* Class II (special controls). The special control is “Class II Special Controls Guidance Document: Cyclosporine and Tacrolimus Assays; Guidance for Industry and FDA.” See § 862.1(d) for the availability of this guidance document. ## Predicate Devices - Abbott IMx® Tacrolimus II Assay and Pretreatment Reagent ([P970007](/device/P970007.md)) ## Reference Devices - liquid chromatography / mass spectrometry (LC/MS) ## Submission Summary (Full Text) > This content was OCRed from public FDA records by [Innolitics](https://innolitics.com). If you use, quote, summarize, crawl, or train on this content, cite Innolitics at https://innolitics.com. > > Innolitics is a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices, including [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/). {0}------------------------------------------------ K060385 Dade Behring Inc. 510(k) Premarket Notification e-submission 510(x) Premail.co. Homes Assay and Emit® 2000 Tacrolimus Sample Pretreatment Reagent ## 510(k) Summary Emit® 2000 Tacrolimus Assay Emit® 2000 Tacrolimus Sample Pretreatment Reagent This summary of 510(k) safety and effectiveness information is submitted in accordance with the requirements of SMDA 1990 and 21 CFR §807.92. The assigned 510(k) number is: ### Manufacturer's Name, Address, Telephone, and Contact Person, Date of 1. Preparation Manufacturer: Dade Behring Inc. 20400 Mariani Ave. Cupertino, CA 95014 Contact Information: Dade Behring Inc. P.O. Box 6101 Newark, DE 19714 Attn: Yuk-Ting Lewis Tel: 302-631-7626 Date of Preparation: February 7, 2006 #### Device Name / Classification 2. Emit® 2000 Tacrolimus Assay / Class II Emit@ 2000 Tacrolimus Sample Pretreatment Reagent / Class II #### 3. Identification of the Predicate Device Abbott IMx® Tacrolimus II Assay and Pretreatment Reagent, P970007 (Note: Tacrolimus test systems have been reclassified into Class II since the predicate was approved.) {1}------------------------------------------------ Dade Behring Inc. 510/k) Premarket Notification e-submission Emit® 2000 Tacrolimus Assay and Emit® 2000 Tacrolimus Sample Pretreatment Reagent #### 4. Device Description The Emit® 2000 Tacrolimus Assay is for in vitro diagnostic use for the quantitative analysis of tacrolimus and metabolite in human whole blood as an aid in the management of tacrolimus therapy in liver and kidney transplant patients. The Emit® 2000 Tacrolimus Assay is comprised of an antibody reagent, a buffer reagent and an enzyme reagent. This assay contains mouse monoclonal antibodies with a high specificity for tacrolimus. The Emit® 2000 Tacrolimus Sample Pretreatment Reagent is an accessory reagent for use with the Emit® 2000 Tacrolimus Assay. The Emit® 2000 Tacrolimus Sample Pretreatment Reagent is used to pretreat the whole blood samples, calibrators, and controls prior to testing with the Emit® 2000 Tacrolimus Assay. The pretreatment process lyses the cells, extracts the tacrolimus, and precipitates most of the blood proteins. The pretreated samples are centrifuged, and an aliquot of the resulting supernatant containing tacrolimus is then assayed using the Emit® 2000 Tacrolimus Assay. #### 5. Device Intended Use The Emit® 2000 Tacrolimus Assay is for in vitro quantitative analysis of tacrolimus and metabolite in human whole blood as an aid in the management of tacrolimus therapy in liver and kidney transplant patients. The Emit® 2000 Tacrolimus Sample Pretreatment Reagent is an accessory reagent for use with the Emit® 2000 Tacrolimus Assay. #### Medical device to which equivalence is claimed and comparison information 6. The Emit® 2000 Tacrolimus Assay and EMIT® 2000 Pretreatment Reagent are substantially equivalent in intended use and technological characteristics to the Abbott IMx® Tacrolimus II Assay and Pretreatment Reagent. Both devices are immunoassays intended for use in the quantitative measurement of tacrolimus in human whole blood. Both devices require a manual pretreatment. The Emit® 2000 Tacrolimus Assay has an assay range of 2-30 ng/mL. The Abbott IMx Tacrolimus II Assay has an assay range of 1.5-30 ng/mL. {2}------------------------------------------------ Dade Behring Inc. 510(k) Premarket Notification e-submission Emit® 2000 Tacrolimus Assay and Emit® 2000 Tacrolimus Sample Pretreatment Reagent ## Comparison Information Method comparison studies were conducted at two external sites comparing the Emit® 2000 Tacrolimus Assay against two predicates: - liquid chromatography / mass spectrometry (LC/MS) and . - . Abbott IMx® Tacrolimus II Assay. Samples from 2 transplant groups (liver and kidney) were included in the studies. The data from both sites were pooled and analyzed by linear regression. | Comparative Method | | | | | |---------------------------------|-------|-----------|-------|-----| | LC/MS/MS | Slope | Intercept | r | n | | All samples | 1.15 | -0.33 | 0.940 | 197 | | Kidney | 1.10 | -0.12 | 0.899 | 90 | | Liver | 1.01 | 0.35 | 0.946 | 65 | | Abbott IMx® Tacrolimus II Assay | | | | | | All samples | 0.92 | -0.04 | 0.881 | 192 | | Kidney | 0.79 | 0.87 | 0.863 | 88 | | Liver | 0.83 | 0.69 | 0.812 | 62 | {3}------------------------------------------------ DEPARTMENT OF HEALTH & HUMAN SERVICES Image /page/3/Picture/1 description: The image shows the logo for the Department of Health and Human Services. The logo is a circular seal with the words "DEPARTMENT OF HEALTH & HUMAN SERVICES" written around the perimeter. Inside the circle is a stylized image of an eagle with its wings spread. Public Health Service Food and Drug Administration 2098 Gaither Road Rockville MD 20850 6 2006 APR Ms. Yuk-Ting Lewis Regulatory Affairs & Compliance Manager Dade Behring Inc. P.O. Box 6101, M/S 514 Newark DE 19714-6101 Re: k060385 > Trade/Device Name: Emit®2000 Tacrolimus Assay Emit®2000 Tacrolimus Sample Pretreatment Reagent Regulation Number: 21 CFR§ 862.1678 Regulation Name: Tacrolimus test system Regulatory Class: Class II Product Code: MLM Dated: February 10, 2006 Received: February 14, 2006 Dear Ms. Lewis: We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food. Drug. and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820). {4}------------------------------------------------ Page 2 - This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market. If you desire specific information about the application of labeling requirements to your device, or questions on the promotion and advertising of your device, please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (240) 276-0484. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html. Sincerely vours. Alberto G Alberto Gutierrez, Ph.D. Director Division of Chemistry and Toxicology Office of In Vitro Diagnostic Device Evaluation and Safety Center for Devices and Radiological Health Enclosure {5}------------------------------------------------ # Indications for Use k 060388 510(k) Number (if known): Emit® 2000 Tacrolimus Assay Device Name: Emit® 2000 Tacrolimus Sample Pretreatment Reagent Indications For Use: The Emit® 2000 Tacrolimus Assay is for in vitro quantitative analysis of tacrolimus and metabolite in human whole blood as an aid in the management of tacrolimus therapy in liver and kidney transplant patients. The Emit® 2000 Tacrolimus Sample Pretreatment Reagent is an accessory reagent for use with the Emit® 2000 Tacrolimus Assay. Prescription Use ਮ (Part 21 CFR 801 Subpart D) AND/OR Over-The-Counter Use _________________________________________________________________________________________________________________________________________________________ (21 CFR 801) (PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED) Concurrence of CDRH, Office of In Vitro Diagnostic Devices (OIVD) C.J.C. e of In Vito Diagnostic Device bation and Safety 060385 Page I of I --- **Source:** [https://fda.innolitics.com/submissions/CH/subpart-b%E2%80%94clinical-chemistry-test-systems/MLM/K060385](https://fda.innolitics.com/submissions/CH/subpart-b%E2%80%94clinical-chemistry-test-systems/MLM/K060385) **Published by [Innolitics](https://innolitics.com)** — a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices. If you're preparing [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/), [get in touch](https://innolitics.com/contact). **Cite:** Innolitics at https://innolitics.com